Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed) Sublocade (buprenorphine extended-release) 300 mg/1.5 mL Injection (USA)
Section 19A approved medicine
(Approval lapsed) Sublocade (buprenorphine extended-release) 300 mg/1.5 mL Injection (USA)
Section 19A approval holder
Indivior Pty Ltd ABN 22 169 280 102
Phone
02 9025 0200
Approved until
Status
Expired
Medicines in short supply/unavailable
SUBLOCADE (buprenorphine modified-release) 300 mg/1.5 mL Injection AUST R 303753
Indication(s)
SUBLOCADE is indicated for maintenance treatment of opioid dependence, within a framework of medical, social and psychological treatment.